Brokerages Expect Cue Biopharma Inc (NASDAQ:CUE) Will Post Quarterly Sales of $1.00 Million

Brokerages forecast that Cue Biopharma Inc (NASDAQ:CUE) will report sales of $1.00 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Cue Biopharma’s earnings. The lowest sales estimate is $970,000.00 and the highest is $1.02 million. Cue Biopharma reported sales of $980,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 2%. The firm is expected to issue its next quarterly earnings results on Thursday, November 5th.

According to Zacks, analysts expect that Cue Biopharma will report full year sales of $6.34 million for the current year, with estimates ranging from $3.81 million to $8.70 million. For the next financial year, analysts expect that the business will report sales of $11.63 million, with estimates ranging from $1.49 million to $19.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Cue Biopharma.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings data on Monday, August 31st. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. Cue Biopharma had a negative net margin of 987.00% and a negative return on equity of 76.44%.

Several analysts have issued reports on CUE shares. BidaskClub lowered shares of Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 26th. Oppenheimer restated a “buy” rating and issued a $32.00 price target on shares of Cue Biopharma in a research report on Tuesday, September 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Cue Biopharma presently has an average rating of “Hold” and an average target price of $31.00.

In other news, insider Anish Suri sold 5,800 shares of the firm’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $20.01, for a total transaction of $116,058.00. Following the completion of the transaction, the insider now directly owns 36,558 shares of the company’s stock, valued at approximately $731,525.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Colin Sandercock sold 6,425 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $20.00, for a total transaction of $128,500.00. Following the transaction, the senior vice president now directly owns 23,550 shares of the company’s stock, valued at $471,000. The disclosure for this sale can be found here. Insiders have sold a total of 26,299 shares of company stock valued at $526,046 over the last ninety days. 9.50% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Schroder Investment Management Group lifted its holdings in Cue Biopharma by 0.5% during the 1st quarter. Schroder Investment Management Group now owns 93,148 shares of the company’s stock valued at $1,334,000 after purchasing an additional 420 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Cue Biopharma by 1.8% in the first quarter. Rhumbline Advisers now owns 24,631 shares of the company’s stock worth $350,000 after acquiring an additional 425 shares during the last quarter. Doheny Asset Management CA raised its stake in shares of Cue Biopharma by 4.1% in the second quarter. Doheny Asset Management CA now owns 12,660 shares of the company’s stock worth $310,000 after acquiring an additional 500 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Cue Biopharma by 13.8% in the first quarter. Victory Capital Management Inc. now owns 4,310 shares of the company’s stock worth $61,000 after acquiring an additional 522 shares during the last quarter. Finally, Ameritas Investment Partners Inc. raised its stake in shares of Cue Biopharma by 55.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,450 shares of the company’s stock worth $60,000 after acquiring an additional 874 shares during the last quarter. 54.40% of the stock is owned by hedge funds and other institutional investors.

Shares of Cue Biopharma stock traded up $0.09 during trading on Friday, reaching $17.30. The company had a trading volume of 1,088,749 shares, compared to its average volume of 300,487. Cue Biopharma has a fifty-two week low of $6.95 and a fifty-two week high of $31.69. The firm’s fifty day moving average is $18.60 and its 200-day moving average is $20.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.94 and a current ratio of 5.94. The company has a market cap of $510.28 million, a price-to-earnings ratio of -11.23 and a beta of 1.82.

About Cue Biopharma

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Featured Story: What is a Call Option?

Get a free copy of the Zacks research report on Cue Biopharma (CUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.